Antiva Biosciences is a biopharmaceutical company developing therapeutics for the treatment of diseases caused by HPV infection.
Antiva Biosciences has raised $53.0M in total funding. The most recent round was Series E. The last funding was announced in April 2023.
Antiva Biosciences's investors include Gaingels, Hillhouse Investment, Mana Ventures, OUP (Osage University Partners), Google Ventures.
Antiva Biosciences is headquartered in Del Mar, United States.
Antiva Biosciences is a biopharmaceutical company developing therapeutics for the treatment of diseases caused by HPV infection.
Antiva Biosciences is at the Series E stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Antiva Biosciences — Funding & Investors." VCBacked, April 27, 2023, https://www.vcbacked.co/company/antiva-biosciences. Accessed July 19, 2026.
VCBacked. (2023). Antiva Biosciences — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/antiva-biosciences
{{cite web |title=Antiva Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/antiva-biosciences |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated